ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Ovarian Cancer
Cancer
Colorectal Cancer
Endometrial Cancer

Triple Negative Breast Cancer trials near Taipei City, TWN:

Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (ESCALATE)

in augmenting neoadjuvant therapy for patients with premenopausal breast cancer.For triple negative breast...

Enrolling
Triple Negative Breast Cancer
Premenopausal Breast Cancer
Drug: Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg

Phase 2

National Taiwan University
National Taiwan University

Taipei, Taiwan

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Trastuzumab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Taipei, Taiwan and 31 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Taipei, Taiwan and 374 other locations

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Active, not recruiting
Breast Cancer
Drug: Tobemstomig
Drug: Nab-Paclitaxel

Phase 2

Roche
Roche

Taipei, Taiwan and 38 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Taipei, Taiwan and 506 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Taipei, Taiwan and 227 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Active, not recruiting
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Taipei, Taiwan and 275 other locations

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low ...

Enrolling
Breast Cancer
Breast Neoplasms
Drug: Epirubicin hydrochloride
Drug: Cyclophosphamide

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Taiwan and 16 other locations

This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with...

Active, not recruiting
Triple Negative Breast Cancer
Microsatellite Stable Colorectal Cancer
Drug: DKY709
Drug: PDR001

Phase 1

Novartis
Novartis

Taipei, Taiwan and 8 other locations

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-...

Active, not recruiting
Triple Negative Breast Cancer
Biological: adagloxad simolenin combined with OBI-821
Other: Standard of care treatment

Phase 3

OBI Pharma

Taipei, Taiwan and 128 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems